ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

osimertinib

Also written as “Osimertinib”, “AZD9291” and “AZD9291 tablet dosing”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Neoplasms · Renal Insufficiency · Carcinoma, led by 3 companies.

Drug pageOsimertinib: every studyAll 130 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 20, 201942 company-led studies, 15 open or runningNext primary completion: Feb 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only3914 open or runningphase 4since Feb 20, 2019Feb 25, 2013Feb 22, 2027phase 3 · NCT05629234
Eli Lilly21 open or runningphase 3since Apr 3, 2015Apr 3, 2015none ahead
Novartisits history only10 open or runningphase 3since Mar 22, 2021Mar 22, 2021none ahead

Also a collaborator on its studies: Parexel, TigerMed and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2015First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT02411448 · 545 enrolled · United States, Canada, France and more
  2. May 31, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungNCT02789345 · 29 enrolled · United States, France, Korea, Republic of and more

TargetBeta

EGFR →read by rule
“A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 2 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more1CompletedOct 19, 201729
NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more3Active, not recruitingJan 23, 2019545

How it is read

Names in the registry

  • “Osimertinib”, 14 entries
  • “AZD9291”, 14 entries
  • “AZD9291 tablet dosing”, 5 entries
  • “AZD9291 Dosing”, 2 entries
  • “Part A - AZD9291 in combination with AZD6094”, 1 entry

Codes read as this program: AZD9291.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.